Company news

Connect Biopharma Holdings Limited news in 2025

Connect Biopharma Holdings Limited's news releases, calls and decks from 2025, newest first.

View company

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

November 24, 2025

Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

November 14, 2025

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

November 11, 2025

Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3

October 30, 2025

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

September 29, 2025

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

September 3, 2025

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

September 2, 2025

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

August 27, 2025

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

August 14, 2025

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

July 21, 2025

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

July 20, 2025

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

July 18, 2025

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 16, 2025

Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China

July 9, 2025

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

June 13, 2025

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

June 2, 2025

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

May 28, 2025

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

May 20, 2025

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

May 14, 2025

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

May 12, 2025

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

April 23, 2025

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

March 31, 2025

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

March 30, 2025

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

March 30, 2025

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

March 27, 2025